Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Histone deacetylase inhibitor therapy in epithelial ovarian cancer.

Takai N, Narahara H.

J Oncol. 2010;2010:458431. doi: 10.1155/2010/458431. Epub 2009 Dec 20.

2.

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.

Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA.

Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7. doi: 10.1093/nar/gkp995. Epub 2009 Nov 11.

3.

Clinical studies of histone deacetylase inhibitors.

Prince HM, Bishton MJ, Harrison SJ.

Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Review.

4.

Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.

Marshall JC, Lee JH, Steeg PS.

Mol Cell Biochem. 2009 Sep;329(1-2):115-20. doi: 10.1007/s11010-009-0116-3. Epub 2009 Apr 23.

5.

Biomarkers for predicting clinical responses to HDAC inhibitors.

Stimson L, La Thangue NB.

Cancer Lett. 2009 Aug 8;280(2):177-83. doi: 10.1016/j.canlet.2009.03.016. Epub 2009 Apr 10. Review.

PMID:
19362413
6.

The biology of chromatin remodeling complexes.

Clapier CR, Cairns BR.

Annu Rev Biochem. 2009;78:273-304. doi: 10.1146/annurev.biochem.77.062706.153223. Review.

PMID:
19355820
7.

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP.

J Thorac Oncol. 2009 Feb;4(2):161-6. doi: 10.1097/JTO.0b013e318194fae7.

8.

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.

Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A.

Br J Cancer. 2009 Jan 13;100(1):28-36. doi: 10.1038/sj.bjc.6604817.

9.

HDAC family: What are the cancer relevant targets?

Witt O, Deubzer HE, Milde T, Oehme I.

Cancer Lett. 2009 May 8;277(1):8-21. doi: 10.1016/j.canlet.2008.08.016. Epub 2008 Sep 27. Review.

PMID:
18824292
10.

Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.

Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS.

Cancer Biol Ther. 2008 Sep;7(9):1388-97. Epub 2008 Sep 2.

PMID:
18708766
11.

Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.

Crabb SJ, Howell M, Rogers H, Ishfaq M, Yurek-George A, Carey K, Pickering BM, East P, Mitter R, Maeda S, Johnson PW, Townsend P, Shin-ya K, Yoshida M, Ganesan A, Packham G.

Biochem Pharmacol. 2008 Aug 15;76(4):463-75. doi: 10.1016/j.bcp.2008.06.004. Epub 2008 Jun 20.

PMID:
18611394
12.

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.

Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S.

Mol Cancer Ther. 2008 Jul;7(7):1923-30. doi: 10.1158/1535-7163.MCT-07-2140. Epub 2008 Jul 7.

13.

Isoform-selective histone deacetylase inhibitors.

Bieliauskas AV, Pflum MK.

Chem Soc Rev. 2008 Jul;37(7):1402-13. doi: 10.1039/b703830p. Epub 2008 May 8. Review.

14.
15.

Isoform-selective histone deacetylase inhibitors.

Itoh Y, Suzuki T, Miyata N.

Curr Pharm Des. 2008;14(6):529-44. Review.

PMID:
18336298
16.

Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.

Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, Zhou W, Liu X, Yang J, Zheng Z, Zhang H, Feng J, Yang Y, Wang H, Zhu WG.

Mol Cell Biol. 2008 May;28(10):3219-35. doi: 10.1128/MCB.01516-07. Epub 2008 Mar 10.

17.

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez-Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Dueñas-González A.

Ann Oncol. 2007 Sep;18(9):1529-38.

PMID:
17761710
18.

Regulation of protein turnover by acetyltransferases and deacetylases.

Sadoul K, Boyault C, Pabion M, Khochbin S.

Biochimie. 2008 Feb;90(2):306-12. Epub 2007 Jul 1. Review.

PMID:
17681659
19.

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

Duvic M, Vu J.

Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20. Review.

PMID:
17594194
20.

Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.

Riester D, Hildmann C, Schwienhorst A.

Appl Microbiol Biotechnol. 2007 Jun;75(3):499-514. Epub 2007 Mar 22. Review.

PMID:
17377788

Supplemental Content

Support Center